Takeda pays $5M upfront to license antibodies for celiac disease drug development
Takeda is working on adding another celiac disease candidate to its pipeline, inking a licensing deal with Innate Pharma, allowing it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
